Columbus OH 子宫内膜癌临床试验
25项针对 子宫内膜癌的研究正在 Columbus及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- 以及另外 13 项
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
招募中1 期
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- 以及另外 8 项
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
招募中1/2 期
- The Ohio State University Wexner Medical Center, Columbus
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
招募中1/2 期
- The Ohio State University Wexner Medical Center, Columbus
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
招募中2 期
- Ohio State University Comprehensive, Columbus
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
招募中2 期
- Research Site, Columbus
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
招募中3 期
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
招募中3 期
- Ohio State University, Hilliard · 距离 10 英里
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
招募中1 期
- The Ohio State University (OSU) Wexner Medical Center, Columbus
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
招募中3 期
- Research Site, Columbus
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
招募中1 期
- The Ohio State University, Columbus
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
招募中1/2 期
- Research Site, Columbus
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
招募中2 期
- Ohio State University, Hilliard · 距离 10 英里
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
招募中1 期
- Ohio State University Wexner Medical Center, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The Ohio State University Comprehensive Cancer Center, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
招募中3 期
- Research Site, Columbus
- Research Site, Hilliard · 距离 10 英里
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
招募中1/2 期
- Stefanie Spielman Comprehensive Breast Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
招募中1 期
- The Ohio State University (OSU) Wexner Medical Center, Columbus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- Stefanie Spielman Comprehensive Breast Center, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
招募中1/2 期
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Columbus
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
招募中2/3 期
- OhioHealth Institute, Columbus
其他城市的 子宫内膜癌试验
- Houston, TX68 项研究
- New York City, NY52 项研究
- Boston, MA50 项研究
- Arlington, VA39 项研究
- Nashville, TN38 项研究
- Los Angeles, CA34 项研究
- St. Louis, MO29 项研究
- Philadelphia, PA28 项研究
- San Antonio, TX27 项研究
- Chicago, IL25 项研究
- Queens, NY25 项研究
- Oklahoma City, OK25 项研究
Columbus的其他研究
- 非小细胞肺癌56 项研究
- 乳腺癌39 项研究
- 卵巢癌39 项研究
- 癌症（所有类型）38 项研究
- 肺癌37 项研究
- 急性髓系白血病35 项研究
- 慢性淋巴细胞白血病28 项研究
- 转移性癌症27 项研究
- 结直肠癌24 项研究
- 前列腺癌24 项研究
- 多发性骨髓瘤24 项研究
- 黑色素瘤21 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。